Helm F C, Frankus E, Friderichs E, Graudums I, Flohé L
Arzneimittelforschung. 1981;31(6):941-9.
Compounds differing from thalidomide in either the phthalimide or the 2,6-dioxopiperidine moiety of the molecule were synthetized and tested for teratogenic potency in White New Zealand rabbits. Both the 2,6-dioxopiperidine and 2-oxopiperidine derivatives of phthalimide and phthalimidine were found to be highly teratogenic. A somewhat higher teratogenic potential appeared to be associated with the 2,6-dioxopiperidine derivatives. The most potent teratogen investigated was clearly 3-(1,3-dihydro-1-oxo2H-isoindol-2-yl)-2,6-dioxopiperidine (EM12). Compounds in which the phthalimide ring was replaced by 2,3-dihydro-1,1-dioxido-3-oxo-1,2-benzisothiazol, did not induce any embryopathic effect differing from control data. No consistent correlation between teratogenic activity and sedative properties of the compounds was detected. The results are discussed in respect to current views of the molecular mechanism leading to thalidomide embryopathy.
合成了在分子的邻苯二甲酰亚胺或2,6 - 二氧代哌啶部分与沙利度胺不同的化合物,并在新西兰白兔中测试其致畸效力。发现邻苯二甲酰亚胺和邻苯二甲亚胺的2,6 - 二氧代哌啶和2 - 氧代哌啶衍生物均具有高度致畸性。2,6 - 二氧代哌啶衍生物似乎具有略高的致畸潜力。所研究的最有效的致畸剂显然是3-(1,3 - 二氢 - 1 - 氧代 - 2H - 异吲哚 - 2 - 基)-2,6 - 二氧代哌啶(EM12)。其中邻苯二甲酰亚胺环被2,3 - 二氢 - 1,1 - 二氧化 - 3 - 氧代 - 1,2 - 苯并异噻唑取代的化合物未诱导出与对照数据不同的任何胚胎病变效应。未检测到化合物的致畸活性与镇静特性之间存在一致的相关性。就导致沙利度胺胚胎病的分子机制的当前观点对结果进行了讨论。